Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line
Biochemical PharmacologyPublished 1 April 1994
V. D. Gupta, Narayana Kamath, George T. Tkalcevic, Shivendra V. Singh
Citations10
SJR quartileQ1
SJR score1.60
SNIP1.24
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
The tumor cell growth inhibitory activity of tamoxifen was enhanced significantly by verapamil treatment in an estrogen receptor positive human breast cancer cell line, MCF-7. Treatment of MCF-7 cells with 5 and 10 micrograms/mL verapamil produced a 1.8- and 2.8-fold increase, respectively, in tamoxifen activity. Unlike reversal of multi-drug resistance, the verapamil-mediated increase in tamoxifen activity was not associated with enhanced drug accumulation. Tamoxifen treatment alone or in combination with verapamil did not affect the activity of protein kinase C, an enzyme implicated in the anti-tumor activity of tamoxifen. Addition of 17 beta-estradiol in the cell survival assay system partially abrogated the modulatory effect of verapamil. These data suggest that potentiation of tamoxifen activity by verapamil may involve interaction of this agent with the estrogen receptor. In conclusion, potentiation of tamoxifen activity by calcium channel blockers represents a novel approach for improving the therapeutic results with tamoxifen in women with breast cancer.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Analytical BiochemistryA Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding
225,378 Citations1976Mark A. Bradford
Analytical BiochemistryA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
211,158 Citations1976Marion M. Bradford
The LancetSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2,189 Citations1992Early Breast Cancer Trialist's Collaborative Group
Recent results in cancer research/Recent Results in Cancer ResearchSystemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy:133 Randomised Trials involoving 31 000 Recurrences and 24 000 Deaths Among 75 000 Women (Summary)
965 Citations1993Richárd Pető, R. Peto
In a worldwide collaboration, information was sought and centrally checked on mortality and recurrence for each woman in any randomised trial that began before 1985 of any aspect of systemic adjuvant therapy for early breast cancer.
PubMedThe effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
809 Citations1976Marc E. Lippman, Gall Bolan +1 more
One of six lines of human breast cancer maintained in long-term tissue culture for at least 1 year and examined for estrogen responsiveness, MCF-7, shows marked stimulation of macromolecular synthesis and cell division with physiological concentrations of estradiol.
PubMedInhibition of protein kinase C by tamoxifen.
468 Citations1985C A O'Brian, Rob M. J. Liskamp +2 more
These findings suggest that the growth-inhibitory and cytotoxic effects of tamoxifen, which have been observed at microM concentrations of the drug, may be in part due to its effects on protein kinase C.
ScienceReversal of Adriamycin Resistance by Verapamil in Human Ovarian Cancer
399 Citations1984Alfred M. Rogan, Thomas C. Hamilton +3 more
Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly resistant cells.
NatureHigh-affinity anti-oestrogen binding site distinct from the oestrogen receptor
361 Citations1980Robert L. Sutherland, Leigh C. Murphy +4 more
A further high-affinity, anti-oestrogen binding site is reported which may have a role in regulating the effects of non-steroidal anti-Oestrogens.
British Journal of CancerControlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
250 Citations1988Analysis at Eight Years by 'Nolvadex'
At a maximum follow up of 8 years in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxIFen daily for 2 years.
Methods in enzymology on CD-ROM/Methods in enzymology[24] Assay and purification of protein kinase C
160 Citations1986Tatsuro Kitano, Masayoshi Go +2 more
PubMedEffect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.
118 Citations1989Richard B. Colletti, J D Roberts +2 more
It is speculated that the antitumor action of tamoxifen in breast cancer is due in part to suppression of IGF-I, which is decreased in malnutrition, decline with advancing age, and are influenced by estrogen.
PubMedEffects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro.
95 Citations1983Roger R. Reddel, Leigh C. Murphy +1 more
Data support the concept that estrogens and antiestrogens compete for a common event which regulates the rate of cell proliferation probably by controlling the proportion of cells entering S phase and 17 beta-estradiol-irreversible mechanisms are also involved in antiestrogen action in vitro.
PubMedCalcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line.
77 Citations1987David A. Greenberg, Celia L. Carpenter +1 more
The effects of three antineoplastic drugs on K+-stimulated 45Ca2+ uptake through voltage-dependent Ca2+ channels of the PC12 neurosecretory cell line were investigated.
CancerDown-regulation of transforming growth factor-α by tamoxifen in human breast cancer
66 Citations1993Shinzaburo Noguchi, Kazuyoshi Motomura +3 more
The significance of TGF-alpha as an autocrine growth factor appears to be more important in ER-negative and PR-negative breast cancer with high EGFR positivity than in ER’s positive andPR-positive breast cancers with low EGFRPositivity.
American Journal of Clinical OncologyInduction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells
65 Citations1991Cornelius Knabbe, Gerhard Zugmaier +4 more
Droloxifene is a more effective inducer of TGFβ and a more potent growth inhibitor for estrogen responsive human breast cancer cells than tamoxifen and toremifene in vitro, and might also possess a higher antiestrogenic potential in treatment ofhuman breast cancer.
JNCI Journal of the National Cancer InstituteEffect of P-glycoprotein Expression on Sensitivity to Hormones in MCF-7 Human Breast Cancer Cells
57 Citations1992Robert Clarke, Sophie Currier +5 more
MCF-7MDR1 cells provide an important model for study of the interactions of cytotoxic drugs, hormones, and the MDR1 glycoprotein in human hormone-responsive breast cancer cells and indicate an association between overexpression of the M DR1 gene and cross-resistance to progestin and antiestrogen therapies.
Surgical Oncology Clinics of North AmericaHormonal Treatment of Advanced Breast Cancer
34 Citations1995Claudia Tellez, V. Craig Jordan
The strategy of using GnRH agonists for premenopausal patients clearly has merit to produce a chemical oophorectomy and whether the use will be found to be superior to pure antiestrogens, however, must await the completion of comparative clinical studies.